ELV Stock Analysis: Elevance Health | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 80.860m USD | 12M Return: 26% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 681M
EPS Trend: -74.3%
Qual. Beats: 2
Rev. Trend: 97.3%
Qual. Beats: 9
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Elevance Health is a major U.S. health benefits company that operates through four segments: Health Benefits, CarelonRx (pharmacy services), Carelon Services (healthcare-related services), and Corporate & Other. The company serves individual, employer group, Medicare, Medicaid, and federal employee members, offering a range of health plans alongside specialty products such as dental, vision, and stop loss insurance. It also runs home delivery and specialty pharmacies, ambulatory infusion centers, and a broad set of care management, behavioral health, palliative care, virtual care, and payment integrity services. Elevance markets under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands, and is headquartered in Indianapolis.
As one of the largest U.S. managed care insurers, Elevance is an independent licensee of the Blue Cross Blue Shield Association, giving it access to the BlueCard network that allows members to receive covered care across all 50 states. Its Carelon branded services reflect a broader industry shift by large insurers toward vertical integration, combining insurance, pharmacy benefit management, and care delivery capabilities under a single corporate platform. The company was incorporated in 2001 and adopted the Elevance Health name in June 2022, having previously operated as Anthem, Inc.
- CMS Medicare Advantage rate cuts pressure premium margins
- CarelonRx and Carelon Services accelerate revenue diversification
- Medical cost trends and GLP-1 utilization pressure margins
| Net Income: 4.96b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.60 > 1.0 |
| NWC/Revenue: 11.40% < 20% (prev 1.98%; Δ 9.42% < -1%) |
| CFO/TA 0.06 > 3% & CFO 7.46b > Net Income 4.96b |
| Net Debt (-6.47b) to EBITDA (8.01b): -0.81 < 3 |
| Current Ratio: 1.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (217.9m) vs 12m ago -3.50% < -2% |
| Gross Margin: 38.95% > 18% (prev 26.84%; Δ 12.12% > 0.5%) |
| Asset Turnover: 161.9% > 50% (prev 155.2%; Δ 6.74% > 0%) |
| Interest Coverage Ratio: 6.19 > 6 (EBIT TTM 6.99b / Interest Expense TTM 1.13b) |
| A: 0.18 (Total Current Assets 67.2b - Total Current Liabilities 44.3b) / Total Assets 126b |
| B: 0.29 (Retained Earnings 36.7b / Total Assets 126b) |
| C: 0.06 (EBIT TTM 6.99b / Avg Total Assets 124b) |
| D: 0.55 (Book Value of Equity 44.9b / Total Liabilities 81.4b) |
| Altman-Z'' = 3.09 = A |
| DSRI: 1.38 (Receivables 23.4b/15.9b, Revenue 201b/189b) |
| GMI: 0.69 (GM 26.84% / 38.95%) |
| AQI: 0.57 (AQ_t 0.43 / AQ_t-1 0.76) |
| SGI: 1.06 (Revenue 201b / 189b) |
| TATA: -0.02 (NI 4.96b - CFO 7.46b) / TA 126b) |
| Beneish M = -3.21 (Cap -4..+1) = AA |
As of July 19, 2026, the stock is trading at USD 373.11 with a total of 1,939,954 shares traded. Over the past week, the price has changed by -10.36%, over one month by -4.64%, over three months by +15.97% and over the past year by +25.95%.
Current recommended Stop Loss: 354.50 (which is 5% or 1.2 ATR below the current price).
Elevance Health has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy ELV.
- StrongBuy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 447.6 | 20% |
P/E Trailing = 16.5051
P/E Forward = 14.5773
P/S = 0.4021
P/B = 1.8886
P/EG = 1.429
Revenue TTM = 201b USD
EBIT TTM = 6.99b USD
EBITDA TTM = 8.01b USD
Long Term Debt = 30.7b USD (from longTermDebt, last quarter)
Short Term Debt = 375.0m USD (from shortTermDebt, last quarter)
Debt = 31.0b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.47b USD (calculated: Debt 31.0b - CCE 37.5b)
Enterprise Value = 74.4b USD (80.9b + Debt 31.0b - CCE 37.5b)
Interest Coverage Ratio = 6.19 (Ebit TTM 6.99b / Interest Expense TTM 1.13b)
EV/FCF = 11.83x (Enterprise Value 74.4b / FCF TTM 6.29b)
FCF Yield = 8.45% (FCF TTM 6.29b / Enterprise Value 74.4b)
FCF Margin = 3.13% (FCF TTM 6.29b / Revenue TTM 201b)
Net Margin = 2.47% (Net Income TTM 4.96b / Revenue TTM 201b)
Gross Margin = 38.95% ((Revenue TTM 201b - Cost of Revenue TTM 123b) / Revenue TTM)
Gross Margin QoQ = 89.12% (prev 18.14%)
Tobins Q-Ratio = 0.59 (Enterprise Value 74.4b / Total Assets 126b)
Interest Expense / Debt = 3.64% (Interest Expense 1.13b / Debt 31.0b)
Taxrate = 15.61% (915.0m / 5.86b)
NOPAT = 5.90b (EBIT 6.99b * (1 - 15.61%))
Current Ratio = 1.52 (Total Current Assets 67.2b / Total Current Liabilities 44.3b)
Debt / Equity = 0.69 (Debt 31.0b / totalStockholderEquity, last quarter 44.9b)
Debt / EBITDA = -0.81 (Net Debt -6.47b / EBITDA 8.01b)
Debt / FCF = -1.03 (Net Debt -6.47b / FCF TTM 6.29b)
Total Stockholder Equity = 44.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.00% (Net Income 4.96b / Total Assets 126b)
RoE = 11.24% (Net Income TTM 4.96b / Total Stockholder Equity 44.2b)
RoCE = 9.34% (EBIT 6.99b / Capital Employed (Equity 44.2b + L.T.Debt 30.7b))
RoIC = 8.14% (NOPAT 5.90b / Invested Capital 72.5b)
WACC = 5.32% (E(80.9b)/V(112b) * Re(6.19%) + D(31.0b)/V(112b) * Rd(3.64%) * (1-Tc(0.16)))
Discount Rate = 6.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.49 | Cagr: -3.16%
[DCF] Terminal Value 77.97% ; FCFF base≈5.91b ; Y1≈6.77b ; Y5≈9.97b
[DCF] Fair Price = 721.5 (EV 150b - Net Debt -6.47b = Equity 156b / Shares 216.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -74.26 | EPS CAGR: -4.85% | SUE: 1.42 | # QB: 2
Revenue Correlation: 97.31 | Revenue CAGR: 7.79% | SUE: 2.95 | # QB: 9
EPS current Quarter (2026-09-30): EPS=4.72 | Chg30d=-7.34% | Revisions=-25% | Analysts=13
EPS current Year (2026-12-31): EPS=27.07 | Chg30d=+0.63% | Revisions=+0% | GrowthEPS=-10.6% | GrowthRev=-0.9%
EPS next Year (2027-12-31): EPS=29.71 | Chg30d=+1.59% | Revisions=+25% | GrowthEPS=+9.7% | GrowthRev=+2.2%
[Analyst] Revisions Ratio: +0% (up=1, down=1)